top of page
Jin leigang.jpg

Dr. Jin Leigang
金雷鋼

Research Assistant Professor

PhD

jinlghk@hku.hk

HKU link

Field of Research

Endocrinology and Metabolism; Bone and Mineral Research; Renal and Cardiovascular Physiology; Peptide Therapeutics; Exercise Biology

Biography

​​

Dr. Leigang Jin is a Research Assistant Professor in the Department of Medicine at The University of Hong Kong. He completed his Bachelor’s and Master’s degrees at Wenzhou Medical University, and was awarded a PhD in Pharmacology and Pharmacy from The University of Hong Kong in 2020. He subsequently undertook postdoctoral training at The University of Hong Kong under the supervision of Professor Aimin Xu.

 

Dr. Jin’s research focuses on metabolic cardiovascular diseases, with a particular interest in the molecular mechanisms, intervention strategies and translational potential of endocrine fibroblast growth factors (FGFs) in metabolic homeostasis. He has established a strong track record in both basic and clinical research in these areas, with contributions to advancing our understanding of disease mechanisms and therapeutic opportunities.

Publications

  1. Jin L, Diaz-Canestro C, Wang Y, Tse MA, Xu A. Exerkines and cardiometabolic benefits of exercise: from bench to clinic. EMBO Mol Med. 2024 Mar;16(3):432-444. PMID: 38321233. (2023 IF=9.0, JCR ranking Q1, 8/187, Molecular Medicine, Biochemistry, Genetics and Molecular Biology)

  2. Jin L, Geng L, Ying L, Shu L, Ye K, Yang R, Liu Y, Wang Y, Cai Y, Jiang X, Wang Q, Yan X, Liao B, Liu J, Duan F, Sweeney G, Woo CWH, Wang Y, Xia Z, Lian Q, Xu A. FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity. Circulation. 2022 Nov 15;146(20):1537-1557. PMID: 36134579. (2022 IF=39.92, JCR ranking Q1, 1/336, Medicine, Cardiology and Cardiovascular Medicine)

  3. Jin L, Yang R, Geng L, Xu A. Fibroblast Growth Factor-Based Pharmacotherapies for the Treatment of Obesity-Related Metabolic Complications. Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:359-382. PMID: 36100222. (2022 IF=12.5, JCR ranking Q1, 1/123, Pharmacology, Toxicology and Pharmaceutics, Toxicology)

  4. Jin L, Lin Z, Xu A. Fibroblast Growth Factor 21 Protects against Atherosclerosis via Fine-Tuning the Multiorgan Crosstalk. Diabetes Metab J. 2016;40(1):22-31. PMID: 26912152. (IF=5.893, JCR ranking Q1, 40/227, Medicine, Endocrinology, Diabetes and Metabolism)

Awards

  1. Faculty Outstanding Research Output Award. HKU Medicine, 2024.

  2. Excellent Paper, Chinese Doctoral Forum on Endocrinology and Metabolism. Endocrinology and Metabolism Committee, Chinese Society of Pathophysiology, 2023.

  3. Young Investigator Award (Oral presentation). 14th International Symposium on Mechanisms of VasoDilatation, Hong Kong, 2021.

  4. Best Abstract in Basic Science (Poster presentation). 25th Medical Research Conference, HKU, 2020.

Grants

  1. Mechanistic role of fibroblast growth factor 23 in regulating renal metabolic disorders and osteoporosis. General Program Sponsored by Shenzhen Natural Science Foundation in Basic Research Fund. Project Code: JCYJ20250604180820027. 2026-2028. Project leader, PI. Sum funded: 300,000 CNY.

  2. Investigating the Role of FABP4 in Visceral Fat-Induced Cardiac Dysfunction. Seed Fund for Basic Research for New Staff 2024/25, HKU. Project Code: 2401103811. 2025-2027. Project leader, PI. Sum funded: 150,000 HKD.

  3. The role of FABP4 in mediating cardiac dysfunction induced by visceral fat. Young Scientists Fund of the National Natural Science Foundation of China. Project Code: 82401011. 2025-2028. Project leader, PI. Sum funded: 300,000 CNY.

L8, Li Ka Shing Faculty of Medicine, 21 Sassoon Road, Pokfulam, Hong Kong

(852) 3917 9766

antibody@hku.hk

Copyright ©2020 State Key Laboratory of Pharmaceutical Biotechnology.  All Rights Reserved.

bottom of page